Sitemap - 2023 - The Microdose

U.S. congressional hearing on psychedelics; New veteran initiatives in MA and WI; Misleading ketamine ads; and Canadian Senate wants funding for psychedelic therapy

Psychedelic churches and the law: 5 Questions for attorney Allison Hoots

Ten challenges in psychedelic science, TREAT California withdraws ballot initiative, and proposed changes to Oregon’s Psilocybin Services Act

What if someone harms you while you’re on psychedelics?: 5 Questions for social worker Erica Siegal

Ninth Circuit Court of Appeals rules in favor of psilocybin rescheduling petition; Massachusetts ballot initiative advances; new psychedelic ballot initiative in California; and MindMed patents

Psychedelics for addiction recovery: 5 Questions for physician Peter Grinspoon

Two defendants claim drug use as a factor in their alleged crimes; New research on extended bad trips; FDA issues ketamine warning

“I hope the plants will win”: 5 Questions for ethnopharmacologist Matteo Politi

Reporting from the rave underground: 5 Questions for drugs journalist Michelle Lhooq

This is a Warning

Psychedelics users more likely to exhibit conspiracy thinking; California Governor Newsom signs a psychedelics bill; Psychedelics’ and AI’s “world changing” promise

Credentialing psychedelic practitioners: 5 Questions for Board of Psychedelic Medicine and Therapies CEO NiCole Buchanan

MDMA increases feelings of social connectedness — but so does meth; Medical codes for psychedelic-assisted therapy; Portland, Maine considers psychedelics resolution

Psychedelic reform coming soon to a ballot box near you: 5 Questions for New Approach deputy policy director Jared Moffat

Congressman from California introduces national psilocybin legislation; Kentucky holds ibogaine public hearing while California lawmaker removes ibogaine from state’s psychedelics bill

Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth

California psychedelics bill headed to Gov Newsom and proposed ballot initiative will cost $6.6 billion over 30 years; New clinical trial results move MAPS one step closer to FDA approval for MDMA

Engineering non-hallucinogenic psychedelics: 5 Questions for researcher David Olson

New clinical trial results suggest a single psilocybin dose can significantly reduce depression symptoms for weeks; Comments on FDA’s draft psychedelics guidance; MDMA therapy for teens?

Hallucinogen use on the rise in the U.S., Does adding MDMA to psilocybin or LSD result in fewer bad trips? And Cybin acquires Small Pharma

Liability insurance for psychedelics: 5 Questions for insurance expert Leslie Nylund

Self-administering psychedelics to treat OCD; California psychedelics bill on pause, Massachusetts ballot initiatives filed; and new guidelines for psychedelic practitioners

“Net-zero trauma by 2070”: 5 Questions for MAPS founder Rick Doblin

Intergenerational trauma: 5 Questions for Indigenous advocate Susan Beaulieu

Oregon’s first psilocybin client: 5 Questions for retired home builder Jim Carroccio

California ballot initiative proposes $5 billion in bonds for psychedelics research and care; study suggests psilocybin for anorexia patients likely safe; Minneapolis and Santa Barbara decrim

The view from Australia: 5 Questions for psychedelics researcher Paul Liknaitzky

Psilocybin sessions have begun in Oregon, DC-based PAC New Approach enters Massachusetts, and a tangle of patent claims

The wild history of MDMA: 5 Questions for author Rachel Nuwer

Does psilocybin treatment need therapy? Group files for a psychedelics ballot initiative in Massachusetts; A new U.S. national poll asks respondents how they feel about psychedelics

"I was shaking and trembling:" 5 Questions for Indigenous protester Kuthoomi Castro

Australia’s new MDMA and psilocybin prescription program raises concerns for researchers, prompts psychiatrists’ organization to release cautionary memo; psychedelics & U.S. presidential candidates

Jeffrey Sitting Bear, Peyote, and Hippies

Indigenous peyote use: 5 Questions for attorney Steven C. Moore

FDA releases psychedelic recommendations; best practices in obtaining informed consent for psychedelic therapy; new NJ bill, CA bill advances

Dispatches from Denver: Day 4 at Psychedelic Science 2023

Dispatches from Denver: Day 3 at Psychedelic Science 2023

Dispatches from Denver: Day 2 at Psychedelic Science 2023

Dispatches from Denver: Day 1 at Psychedelic Science 2023

Is psychedelic research biased?: 5 Questions for psychiatrist Josh Woolley

New study suggests TrkB receptor is key to psychedelics’ antidepressant effects, U.S. Patent board upholds COMPASS COMP360 patents, and Rhode Island bill advances

Mixing antidepressants and psychedelics: 5 Questions for psychopharmacologist Kelan Thomas

California psychedelics legalization bill advances, Kentucky to spend $42 million on ibogaine research; DC’s psychedelics lobbyists; Is informed consent possible?

UK Members of Parliament call for psilocybin rescheduling, a new psychedelics Action Group in the European Parliament, and was Australia’s psychedelic reform “too fast and too soon”?

Psychedelics for racial trauma: 5 Questions for radio journalist Tonya Mosley

Learning from reverse-engineering psychedelics, the murky future of ketamine telehealth, and who do psychonauts trust?

Developing guidance for psychedelic therapy: 5 Questions for the APA’s Lynn Bufka

Oregon’s first licensed psilocybin service center and next steps on a data privacy bill; a review of psychedelic trials finds poor blinding

Prozac Lessons: 5 Questions for drug historian David Herzberg

American Medical Association assigns billing code for psychedelic therapy; Can psychedelics alter colorblindness?; How should Oregon collect data on psilocybin service users?

“When the policy gets ahead of the science, it's challenging”: 5 Questions for bioethicist Amy McGuire

What’s happening inside the brain on LSD? Colorado psychedelics legislation flies through state Senate, and Oregon gets its first licensed testing lab

Guts, brains, and psychedelics: 5 Questions for psychiatrist John Kelly

The latest in Colorado, new study suggests single psilocybin session could reduce depressive symptoms in cancer patients, and MindMed announces preliminary results, stock soars

5 Questions for Oregon’s first licensed psilocybin manufacturer

Negligible effects of microdosing at home; Usona researchers challenge Church of Psilomethoxin’s claims; and will Massachusetts’ proposed cost cap on MDMA treatment actually help equity?

Psychedelics on campus: 5 Questions for Intercollegiate Psychedelics Network co-founder Victor Acero

Whirling apes and altered consciousness; can Colorado communities opt out of psilocybin services, and establishing psychedelic therapy “gold standards”

Advancing the science: 5 Questions for two National Institutes of Health researchers

Your brain on DMT, Field Trip in a tailspin, a flurry of new bills

Record-sealing for drug convictions: 5 Questions for The Color of Cannabis’s Graydon Washington

Bringing the “Oregon Experiment” to the feds: 5 Questions for U.S. Representative Earl Blumenauer (D-OR)

Synthesis folds; New Rhode Island bill and decrim in Ferndale, Michigan; Psychedelic self-treatment outcomes

Testing psilocybin potency: 5 Questions for laboratory chemist Bjorn Fritzsche

Debate over Oregon psilocybin services data collection roils on, new DEA proposal could mean more ketamine telehealth, and are you experienced?

Psychedelic-assisted therapy and tribal health: 5 Questions for Indigenous scholar Marlena Robbins

Virginia, Washington, Utah bills in peril; Treating mental health issues by getting inside cells; and the EU risks falling behind the U.S. and Australia in psychedelics development

Can AIs provide psychedelic therapy? 5 Questions for chatbot ChatGPT

Legal faceoff between doctor and DEA continues, bills advance in Arizona, Virginia, Hawaii, and Utah, and regulating psychedelics in the EU

Ethical ketamine: 5 Questions for ketamine specialist Raquel Bennett

Australia becomes first country to approve psilocybin and MDMA as medicine; a death knell for mail-order ketamine; and in psilocybin therapy, it’s not just about the psilocybin

Decolonizing psychedelics: 5 Questions for psychedelic facilitator and teacher Charlotte James

Colorado governor announces Natural Medicine Advisory Board appointees, new bills in Utah and New York, and reforming the “regulatory blackhole” of U.S. drug scheduling

When mushrooms meet bureaucracy: 5 Questions for Oregon Psilocybin Services Manager Angela Allbee

Flow state? Psychedelics’ effect on periods, new bills in Massachusetts, Missouri, Oklahoma, Oregon’s contentious new legislation

What is a bad trip? 5 Questions for Jules Evans of The Challenging Psychedelic Experiences Project

Even more psychedelics bills, changing western views on hallucinating, and a new name for 5-MeO-DMT?

Why do plants and fungi produce psychedelics? 5 Questions for evolutionary biology and genetics professor Noah Whiteman

A flurry of state psychedelics bills, atai stock price plummets, the subtypes of psychedelic experiences

The “acid king” prognosticates: 5 Questions for William Leonard Pickard

It’s official in Oregon, the latest in CO, CA, and NY, and psilocybin trip reports from people with bipolar disorder